GlassScriptPhysician profile
Chiara Maruggi
NPI 1578094132
$2,289.72
in general payments reported to CMS, 2019-2025
20 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.22 · 2022: $157 · 2023: $126 · 2024: $683 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,115.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $299.60 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $281.77 | 2024-2025 | Stelara, Tremfya |
| Genzyme Corporation | $249.14 | 2025 | |
| Janssen Biotech, INC. | $222.87 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $215.16 | 2022-2025 | Entyvio, Eohilia |
| Celltrion USA INC. | $183.53 | 2025 | Zymfentra, Vegzelma |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $124.53 | 2023-2024 | Rebyota |
| Novo Nordisk INC | $100.34 | 2024 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $98.92 | 2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.97 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $60.92 | 2024-2025 | Voquezna |
| Pfizer INC. | $60.19 | 2025 | |
| Celgene Corporation | $51.19 | 2024 | Zeposia |
| Vivus LLC | $37.38 | 2024 | Qsymia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $33.38 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $25.66 | 2024 | |
| Ardelyx, INC. | $21.64 | 2025 | Ibsrela |
| Amgen INC. | $17.31 | 2022 | |
| Csl Behring | $17.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chiara Maruggi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.